Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ODAC Veterans Disagree On Value Of Public Hearing At Panel Meetings

Executive Summary

Current and former chairs of FDA’s Oncologic Drugs Advisory Committee debate the usefulness of the public hearing and its impact on committee deliberations.

You may also be interested in...

From Avastin To Zevalin: ODAC’s Most Memorable Moments

The current and former leaders of FDA’s Oncologic Drugs Advisory Committee recount their most memorable moments of service on the panel.

Avastin Clinical Benefit Trumps Anti-Tumor Effect In Glioblastoma, ODAC Says

Demonstration of an anti-tumor effect is not essential for a brain cancer indication if clinical benefit is provided, FDA's Oncology Drugs Advisory Committee indicated March 31 in recommending accelerated approval of Genentech's Avastin to treat relapsed glioblastoma multiforme

Tarceva Pancreatic Cancer Survival Merits Approval, More Study Of Dosing

Genentech/OSI should study sequential dosing of its epidermal growth factor receptor inhibitor Tarceva and Lilly's Gemzar, FDA and Oncologic Drugs Advisory Committee members suggested in recommending supplemental approval of erlotinib for treatment of pancreatic cancer Sept. 13


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts